AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23735512 — intervention group
Group type: EXPERIMENTAL
Intervention: Subendocardial viability ratio (SEVR) in deceased patients
Number of subjects: 212
Study 23735512 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of SEVR values during the study (third tertile)
Number of subjects: 212
Study 21778673 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (45 mg daily) and risedronate sodium (once weekly)
Number of subjects: 231
Study 21778673 — intervention group
Group type: COMPARATOR
Intervention: Placebo and risedronate sodium (once weekly)
Number of subjects: 231
Study 19318702 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of a light diet during labour
Number of subjects: 2426
Study 19318702 — intervention group
Group type: COMPARATOR
Intervention: Water during labour
Number of subjects: 2426
Study 16400468 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate (300 mg continuous intravenous infusion in 500 mL Ringer's solution at 111 mL/h for 4.5 hours)
Number of subjects: 193
Study 16400468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Ringer's solution)
Number of subjects: 193
Study 15301655 — intervention group
Group type: COMPARATOR
Intervention: no‐incentive vouchers
Number of subjects: 125
Study 15301655 — intervention group
Group type: EXPERIMENTAL
Intervention: incentive vouchers alone
Number of subjects: 125
Study 15301655 — intervention group
Group type: EXPERIMENTAL
Intervention: incentive vouchers plus relationship counseling
Number of subjects: 125
Study 11268223 — intervention group
Group type: COMPARATOR
Intervention: Garlic preparations
Number of subjects: 1798
Study 9262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective IVP group (19 IVPs performed)
Number of subjects: 81
Study 9262695 — intervention group
Group type: COMPARATOR
Intervention: Routine IVP group (40 patients)
Number of subjects: 81
Study 9262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective IVP group
Number of subjects: 81
Study 9262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 8335855 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated moisturized air (delivered at 40 L/min and 43 degrees C)
Number of subjects: 0
Study 8335855 — intervention group
Group type: COMPARATOR
Intervention: Room temperature moisturized air
Number of subjects: 0
Study 6387282 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethyl ether extraction
Number of subjects: 0
Study 6387282 — intervention group
Group type: COMPARATOR
Intervention: Ethanol-acetone extraction
Number of subjects: 0
Study 31190822 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-Hz rTMS treatment for 4 weeks
Number of subjects: 60
Study 31190822 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 60
Study 30257695 — intervention group
Group type: EXPERIMENTAL
Intervention: Program Sustainability Action Planning Training and technical assistance
Number of subjects: 24
Study 30257695 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 24
Study 27029775 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cessation programme with optimised text messaging intervention
Number of subjects: 860
Study 27029775 — intervention group
Group type: COMPARATOR
Intervention: Web-based cessation programme alone
Number of subjects: 860
Study 27029775 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 860
Study 24533890 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 90
Study 24533890 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine
Number of subjects: 90
Study 21461716 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (21 patients) - 2 thermomineral water baths daily for 2 weeks
Number of subjects: 50
Study 21461716 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (21 patients)
Number of subjects: 50
Study 21461716 — intervention group
Group type: COMPARATOR
Intervention: Control (24 patients) - continued medical treatment and routine daily life
Number of subjects: 50
Study 21461716 — intervention group
Group type: COMPARATOR
Intervention: Control (24 patients)
Number of subjects: 50
Study 20345032 — intervention group
Group type: EXPERIMENTAL
Intervention: Impacted high tibial osteotomy
Number of subjects: 30
Study 20345032 — intervention group
Group type: COMPARATOR
Intervention: Conventional high tibial osteotomy
Number of subjects: 30
Study 16626957 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy with trace isoflavones (<4 mg)
Number of subjects: 16
Study 16626957 — intervention group
Group type: COMPARATOR
Intervention: Total milk protein
Number of subjects: 16
Study 16626957 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy with 107 mg of total aglycone units of isoflavones
Number of subjects: 16
Study 16710105 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-depreotide SPECT (DEP-SPECT)
Number of subjects: 29
Study 16710105 — intervention group
Group type: COMPARATOR
Intervention: 18F-FDG PET (PET-FDG)
Number of subjects: 29
Study 16710105 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 29
Study 17516694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin XL 10 mg/day
Number of subjects: 0
Study 17516694 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine IR 4 mg/day
Number of subjects: 0
Study 11068350 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 165
Study 11068350 — intervention group
Group type: COMPARATOR
Intervention: Orthodox medicine
Number of subjects: 165
Study 11068350 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary medicine users
Number of subjects: 165
Study 11068350 — intervention group
Group type: COMPARATOR
Intervention: Non-complementary medicine users
Number of subjects: 165
Study 8943602 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol and sufentanil (group A)
Number of subjects: 16
Study 8943602 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anaesthesia with isoflurane and nitrous oxide (group B)
Number of subjects: 16
Study 1624154 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan
Number of subjects: 206
Study 1624154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 6384848 — intervention group
Group type: EXPERIMENTAL
Intervention: butoconazole nitrate cream 2%
Number of subjects: 274
Study 6384848 — intervention group
Group type: COMPARATOR
Intervention: clotrimazole vaginal tablets 200 mg/day
Number of subjects: 274
Study 30668567 — intervention group
Group type: EXPERIMENTAL
Intervention: Head- or full body-ventilated PPE suits equipped with powered-air-purifying-respirators
Number of subjects: 19
Study 28251157 — intervention group
Group type: EXPERIMENTAL
Intervention: ArmAssist robotic training
Number of subjects: 26
Study 28251157 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched conventional arm training)
Number of subjects: 26
Study 25475929 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20mg plus metformin
Number of subjects: 204
Study 25475929 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus metformin
Number of subjects: 204
Study 22967035 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 227
Study 22967035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 21576096 — intervention group
Group type: EXPERIMENTAL
Intervention: Proseal™ LMA (PLMA)
Number of subjects: 120
Study 21576096 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme™ (SLMA)
Number of subjects: 120
Study 19782008 — intervention group
Group type: COMPARATOR
Intervention: HOMA-beta cell index in control subjects
Number of subjects: 32
Study 19782008 — intervention group
Group type: COMPARATOR
Intervention: Stumvoll's early insulin secretion index in CF-NGT patients
Number of subjects: 32
Study 19782008 — intervention group
Group type: COMPARATOR
Intervention: Insulin secretion rate (ISR) in CF-NGT and CFRD groups
Number of subjects: 32
Study 19782008 — intervention group
Group type: COMPARATOR
Intervention: HOMA-beta cell index in CF-NGT patients
Number of subjects: 32
Study 17135618 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT
Number of subjects: 182
Study 17135618 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT+LOV
Number of subjects: 182
Study 17135618 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT+LOV (100% adherent)
Number of subjects: 182
Study 17135618 — intervention group
Group type: COMPARATOR
Intervention: SBT+LOV (<100% adherent)
Number of subjects: 182
Study 12706934 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day for four weeks)
Number of subjects: 45
Study 12706934 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day for four weeks)
Number of subjects: 45
Study 12706934 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 45
Study 10921161 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Zhi Capsules (YZC)
Number of subjects: 0
Study 10921161 — intervention group
Group type: COMPARATOR
Intervention: Control group (Piracetam)
Number of subjects: 0
Study 8769292 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG solution 250 ml twice a day
Number of subjects: 48
Study 8769292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1422792 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cerebellar disease
Number of subjects: 16
Study 1422792 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study 6141335 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-vinyl GABA (3 g daily)
Number of subjects: 24
Study 6141335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6141335 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-vinyl GABA
Number of subjects: 24
Study 30630109 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities for Healthy Living (CHL) obesity prevention program
Number of subjects: 0
Study 29477688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt (350‐mm2 Baerveldt glaucoma implant)
Number of subjects: 242
Study 29477688 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes)
Number of subjects: 242
Study 29477688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt
Number of subjects: 242
Study 29477688 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with MMC
Number of subjects: 242
Study 27456094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of Strength program
Number of subjects: 16
Study 27456094 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 16
Study 24491572 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg alone and gemfibrozil 600 mg BID for 5 days with a single dose of empagliflozin 25 mg on the third day.
Number of subjects: 36
Study 24491572 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg coadministered with rifampicin 600 mg.
Number of subjects: 36
Study 24491572 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg coadministered with probenecid 500 mg BID for 4 days.
Number of subjects: 36
Study 22956656 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intradermal (i.d.) vaccination
Number of subjects: 89
Study 22956656 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intramuscular (i.m.) vaccination
Number of subjects: 89
Study 22956656 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intramuscular (i.m.) vaccination
Number of subjects: 89
Study 22956656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 20119464 — intervention group
Group type: EXPERIMENTAL
Intervention: tapentadol IR (50, 75, or 100 mg every 4 or 6 hours, maximum TDD 500 mg)
Number of subjects: 88
Study 20119464 — intervention group
Group type: EXPERIMENTAL
Intervention: tapentadol ER (100, 150, 200, or 250 mg bid)
Number of subjects: 88
Study 20119464 — intervention group
Group type: COMPARATOR
Intervention: tapentadol IR and tapentadol ER
Number of subjects: 88
Study 17035945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 360
Study 17035945 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 360
Study 16277587 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment before 28 weeks of gestation (N = 580)
Number of subjects: 870
Study 16277587 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving periodontal treatment after delivery (N = 290)
Number of subjects: 870
Study 16277587 — intervention group
Group type: COMPARATOR
Intervention: Periodontal treatment (treatment group) vs. no treatment (control group)
Number of subjects: 870
Study 16277587 — intervention group
Group type: COMPARATOR
Intervention: Periodontal treatment (treatment group) vs. gingivitis risk
Number of subjects: 870
Study 11704445 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 60
Study 11704445 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 60
Study 9627365 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 25
Study 9627365 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg daily added to ERT
Number of subjects: 25
Study 9627365 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) in nonsmoking women
Number of subjects: 25
Study 9627365 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) in cigarette smokers
Number of subjects: 25
Study 8063985 — intervention group
Group type: EXPERIMENTAL
Intervention: GDVM plus ADVANCE
Number of subjects: 78
Study 8063985 — intervention group
Group type: COMPARATOR
Intervention: GDVM alone
Number of subjects: 78
Study 3287837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibric acid and nicotinic acid (Treatment group)
Number of subjects: 555
Study 31166679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen)
Number of subjects: 672
Study 31166679 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen)
Number of subjects: 672
Study 31166679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (in subgroup of 495 patients who received an aromatase inhibitor)
Number of subjects: 672
Study 31166679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy
Number of subjects: 672
Study 28390934 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (IIV4)
Number of subjects: 2278
Study 28390934 — intervention group
Group type: COMPARATOR
Intervention: Comparator quadrivalent inactivated influenza vaccine (IIV4)
Number of subjects: 2278
Study 25168032 — intervention group
Group type: EXPERIMENTAL
Intervention: Income conditions of $280, $127, $70, or $32 per week with prices of $0.12, $0.25, $0.50, and $1.00 per cigarette
Number of subjects: 15
Study 23283585 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 0.5 Gy
Number of subjects: 112
Study 23283585 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1.0 Gy
Number of subjects: 112
Study 21245887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus sporogenes (350,000,000 c.f.u. added to breast milk or formula, once a day)
Number of subjects: 221
Study 21245887 — intervention group
Group type: COMPARATOR
Intervention: Control (no L. sporogenes supplementation)
Number of subjects: 221
Study 18279295 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures adhering to the Belgian Guideline for Prevention of Pressure Ulcers
Number of subjects: 744
Study 18279295 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures not adhering to the Belgian Guideline for Prevention of Pressure Ulcers
Number of subjects: 744
Study 18279295 — intervention group
Group type: EXPERIMENTAL
Intervention: No preventive measures
Number of subjects: 744
Study 18279295 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least one pressure ulcer
Number of subjects: 744
Study 18279295 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal carers informed and motivated by home care nurse
Number of subjects: 744
Study 18279295 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual participation in prevention by patients and informal carers
Number of subjects: 744
Study 16476114 — intervention group
Group type: EXPERIMENTAL
Intervention: Syzygium cumini tea
Number of subjects: 27
Study 16476114 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide tablets
Number of subjects: 27
Study 16476114 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 27
Study 16476114 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 27
Study 12897500 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic whiplash injury patients
Number of subjects: 25
Study 12897500 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 25
Study 11138759 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean participants
Number of subjects: 0
Study 11138759 — intervention group
Group type: COMPARATOR
Intervention: American participants
Number of subjects: 0
Study 9058613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet
Number of subjects: 0
Study 9058613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study 9058613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cidofovir
Number of subjects: 0
Study 9058613 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapies (intraocular injections of ganciclovir and foscarnet)
Number of subjects: 0
Study 9058613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release ganciclovir implant
Number of subjects: 0
Study 9058613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of local and systemic therapies
Number of subjects: 0
Study 8132367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg on the first day, then 300 mg daily)
Number of subjects: 40
Study 8132367 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (0.5 mg/kg body weight) + Flucytosine (3 x 2.5 g daily)
Number of subjects: 40
Study 3590088 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 500 U bd
Number of subjects: 45
Study 3590088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3590088 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 750 U bd
Number of subjects: 45
Study 3590088 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 1000 U bd
Number of subjects: 45
Study 31432716 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use digital flexible ureteroscope (ZebraScope)
Number of subjects: 126
Study 31432716 — intervention group
Group type: COMPARATOR
Intervention: Reusable digital flexible ureteroscope (URF-V)
Number of subjects: 126
Study 30585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic mechanical allodynia (DMA) at the control site
Number of subjects: 74
Study 30585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory hypesthesia at the control site
Number of subjects: 74
Study 30585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical gain/loss with normal thermal detection at the affected site
Number of subjects: 74
Study 30585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical gain/loss with normal thermal detection at the control site
Number of subjects: 74
Study 30585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Disability Index
Number of subjects: 74
Study 30585985 — intervention group
Group type: EXPERIMENTAL
Intervention: SES affective pain perception scores
Number of subjects: 74
Study 30585985 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 subscores
Number of subjects: 74
Study 27775461 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX, intra-articular betamethasone and CyA
Number of subjects: 160
Study 27775461 — intervention group
Group type: COMPARATOR
Intervention: Placebo CyA
Number of subjects: 160
Study 25891697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus modified release (TAC-MR) once daily
Number of subjects: 99
Study 25891697 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC) twice daily
Number of subjects: 99
Study 25197696 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain/Loss Sharing and Buyback (GLB) contract combined with Sales Rebate and Penalty (SRP) contract
Number of subjects: 0
Study 25197696 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain/Loss contracts
Number of subjects: 0
Study 25197696 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss aversion analysis
Number of subjects: 0
Study 20964740 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 88
Study 19126556 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless Prima Plus bioprosthesis
Number of subjects: 40
Study 19126556 — intervention group
Group type: COMPARATOR
Intervention: Stented Perimount bioprosthesis
Number of subjects: 40
Study 19126556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17505051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (180 microg)
Number of subjects: 88
Study 15502479 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diquafosol
Number of subjects: 527
Study 15502479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 11983754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy plus adjuvant oophorectomy and tamoxifen during luteal phase (n = 158)
Number of subjects: 565
Study 11983754 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy only (n = 289)
Number of subjects: 565
Study 9817160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized L-NAME (10(-1) M)
Number of subjects: 12
Study 9817160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7714088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed group (n = 7)
Number of subjects: 12
Study 7714088 — intervention group
Group type: COMPARATOR
Intervention: Fasted group (n = 10)
Number of subjects: 12